Joachim Kreuzburg, Ph.D., CEO of the Sartorius Group, told a press conference that the company achieved all financial targets for fiscal 2013, including growth of 7.7% in consolidated sales revenue of €887.3 million (around $1.22 billion), up from €845.7 million (approximately $1.16 billion) a year ago. He also pointed out that Sartorius’ bioprocess solutions division expanded its portfolio for the biopharma market by acquisitions and its own product development.
“In the lab products & services division, we launched a number of promising new product series and at the same time we phased out a few nonstrategic product lines,” he said.
Dr. Kreuzburg noted that operating profit rose 7.1% and the company’s profit margin reached 19.5%. The number of employees grew to over than 6,000. Sartorius expects sales to grow approximately 8% to 10% in constant currencies for 2014, he added.